Preclinical Safety Assessment and Mitigation Strategies in Drug Discovery – Focus on Drug-Induced Liver Injury (DILI)

Date: 17 October 2018

Time: 15:00 - 16:00

Tutors: Dr Bryan H. Norman

15:00-16:00 GMT (London)
10:00-11:00 AM ET (New York)

A challenging aspect of drug discovery is the mitigation of safety risks that arise during most drug discovery optimization efforts.  This webinar will highlight some of the current best practices and methods used in pharma to identify, understand and mitigate common preclinical safety risks.   It will also explore proactive approaches that may help drug-hunters avoid many safety issues on the road to clinical candidate selection and first human dose.  There will be specific emphasis on assessing and mitigating risks associated with drug-induced liver injury (DILI).  Several DILI-related mechanisms, such as BSEP inhibition, bioactivation and reactive metabolite formation will be discussed.

While the focus is on medicinal chemistry methods, this webinar will benefit all scientists who participate in the cross functional execution of drug discovery programs.

This FREE webinar will be presented by Dr Bryan Norman. Bryan is the tutor on the 2-day course: Preclinical Safety Assessment and Mitigation Strategies in Drug Discovery.

15:00-16:00 GMT (London)
10:00-11:00 AM ET (New York)

Book Now